Clinical Trials Logo
  1. Home
  2. Biliary Atresia
  3. NCT05783518

Effect of Desflurane on Pediatric Acute Respiratory Distress Syndrome After Living Donor Liver Transplant Recipients — EDPARDSLDLTR  

Biliary Atresia Clinical Trial

Official title:
Effect of Desflurane on Pediatric Acute Respiratory Distress Syndrome After Living Donor Liver Transplant Recipients

Clinical Trial Summary

Biliary atresia is a serious congenital anomaly characterized by persistent and progressive cholestatic jaundice. The incidence of biliary atresia is more common in East Asia, especially China, with an incidence of 2 per 10,000 live births. Liver transplantation is the only effective way to treat end-stage liver disease. However, distant organ damage, affecting the heart, brain, kidneys, lungs, and intestines, is still an important factor affecting the long-term survival of children after surgery. Desflurane is a volatile anesthetic commonly used in surgery. In order to observe the effect of desflurane on the incidence of early postoperative pediatric acute respiratory distress syndrome (PARDS) with biliary atresia who underwent living donor liver transplantation, and explore the related mechanism, a total of 165 infant patients underwent living liver transplantation due to biliary atresia from March 2023 to October 2023 are included in our single-center prospective study. They are randomly divided into propofol group (n=55), propofol and desflurane group (n=55) and desflurane group (n=55) according to the difference of intraoperative anesthesia maintenance. Gender, age, height, weight, PELD scores and other preoperative basic data are recorded. Operation time, anhepatic time and intraoperative blood loss volume are recorded. The basic information of liver donors are also recorded. Postoperative mechanical ventilation time, ICU stay time, tacrolimus concentration, total length of hospital stay and mortality during hospitalization are recorded. According to the the definition of PARDS recommended by the 2015 Pediatric Acute Lung Injury Consensus Conference is used as the diagnostic and grading criteria for postoperative PARDS, and the incidence and grading of PARDS within the first seven days after surgery are evaluated in the three groups. Peripheral blood is collected immediately after anesthesia induction, 30min after reperfusion and at the end of surgery to detect serum levels of HMGB1, IL-6 and TNF-α by enzyme linked immunosorbent assay (ELISA).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05783518
Study type Interventional
Source Tianjin First Central Hospital
Contact
Status Not yet recruiting
Phase Phase 4
Start date March 27, 2023
Completion date October 31, 2023
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03667534 - Dry Blood Spot Screening Test for Neonatal Cholestasis Patients
Completed NCT02652533 - Ultrasound Shear Wave Elastography Evaluation of Suspected and Known Biliary Atresia
Completed NCT01443572 - The Comparison of Desflurane and Sevoflurane on Postoperative Recovery and Hepatic Function of Biliary Atresia Patients During Kasai Operation N/A
Recruiting NCT04373941 - Part II: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia Phase 2
Completed NCT01854827 - Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia Phase 1/Phase 2
Completed NCT00007033 - Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease N/A
Recruiting NCT05848310 - Preoperative Serum FGF19 in the Prognosis of Biliary Atresia
Recruiting NCT05072626 - High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia
Completed NCT02292862 - Maternal Microchimerism in Lymph Nodes of Infants With Biliary Atresia at Time of Kasai's Operation N/A
Completed NCT00294684 - A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy N/A
Active, not recruiting NCT02922751 - FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
Recruiting NCT04260503 - Gut Microbiome in Biliary Atresia
Not yet recruiting NCT06260566 - Tolerability of Enteral NAC in Infants Phase 1
Completed NCT01322386 - Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin Phase 1
Recruiting NCT05909033 - Early Predictors for the Short Term Native Liver Survival in Patients With Biliary Atresia After Kasai Procedure
Completed NCT03499249 - N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy Phase 2
Recruiting NCT00345553 - Biliary Atresia Study in Infants and Children
Recruiting NCT05521152 - Norepinephrine for Prevention of Intraoperative Hypotension in Infants Undergoing Kasai Portoenterostomy Phase 3
Not yet recruiting NCT06121375 - Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy Phase 2/Phase 3
Recruiting NCT05399745 - BILACO Trial: Biliary Atresia - a Severe Complex Congenital Liver Disease